Peptide Descriptions

CagriSema Peptide 10mg – Advanced Amylin Analog

CagriSema is an investigational weight-loss and diabetes medication currently in Phase 3 clinical trials. CagriSema  is a once-weekly injectable that combines two different types of drugs into a single treatment to achieve greater results than either could alone.   

1. Key Components

CagriSema is a fixed-dose combination of:

• Semaglutide (2.4 mg): A GLP-1 receptor agonist already well-known as the active ingredient in Ozempic and Wegovy. It mimics a gut hormone to reduce appetite, slow digestion, and improve insulin secretion.   
• Cagrilintide (2.4 mg): A long-acting analog of amylin, a hormone naturally produced by the pancreas alongside insulin. It works by increasing feelings of fullness (satiety) and slowing the rate at which the stomach empties.   

2. How It Works (Mechanism of Action)

The medication uses a “dual-agonist” approach. While semaglutide primarily targets the brain’s appetite centers and gut signals, cagrilintide adds a second layer of appetite suppression by mimicking amylin. Together, they target multiple pathways that regulate hunger, leading to what some researchers call a “synergistic effect” for weight loss.   

3. Clinical Trial Results

Recent data from the REDEFINE clinical program has shown significant efficacy:

• Weight Loss: In the REDEFINE 1 trial, adults without diabetes lost an average of 20.4% to 22.7% of their body weight over 68 weeks.
• Type 2 Diabetes: In the REDEFINE 2 trial, patients with type 2 diabetes achieved a 15.7% weight reduction and significantly improved blood sugar (HbA1c) levels.
• Comparison: Trials have generally shown that CagriSema outperforms semaglutide alone and cagrilintide alone in both weight loss and glucose control.   

4. Side Effects & Status

• Side Effects: The most common side effects are gastrointestinal, similar to other GLP-1 drugs, including nausea, vomiting, diarrhea, and constipation.   
• FDA Status: As of late 2025/early 2026, Novo Nordisk has submitted a New Drug Application (NDA) to the FDA. If approved, it is expected to become a major competitor to other high-efficacy treatments like Zepbound.